In this dynamic political, economic and social environment, the Corporate Affairs function is crucial to any biopharmaceutical company's economic health and survival. Top companies recognize the value of Corporate Affairs and see it as a strategic tool -- building company reputation and brand, as well as forging strong corporate relationships with external stakeholders. A strong Corporate Affairs function can drive corporate success.
This report provides benchmarks to identify key Corporate Affairs resources, issues, services and priorities across the bio-pharmaceutical and medical device industry and other regulated business sectors. This report examines performance excellence by probing the most critical Corporate Affairs specialty groups.
Also, this study presents different organizational models for Corporate Affairs and current trends in staffing and budgets for these groups as well.
Corporate Affairs leaders can use this research to compare their organizational structure and resourcing with those of leading organizations.
This multi-industry benchmarking study is aimed at examining key trends that drive structural changes in corporate affairs and variations in service level priorities. This study comprises valuable metrics and actionable insights that can be used to compare current practices at organizations with best-in-class approaches in maintaining a high-performing Corporate Affairs function.
This benchmarking research included 28 corporate affairs executives and managers at 27 leading bio-pharmaceutical, healthcare and non-healthcare companies.
Field interviews and study analysis produced many observations and benchmark findings. Key study insights reflect the inter-related evolution of a company’s commercial structure and indicate when organizations embrace organizational change –such as business unit structures -to support their growth and profitability